Yes you're right. I was expecting K2U dollars but re-checked the 1/4 rly dates against the release date of K2U.
"$87,501 relates to Managing Director remuneration"
$350,000 as an annual salary. I am not against good salaries. However, I think that shareholders should see some return on the 350k we are investing in the MD. Maybe more news on current deals e.g. Think there might have been some info on that. Maybe some of what they are doing is 'commercial in confidence' stuff? Willing to give benefit of doubt.
Not talking it down - been here since GAL days - but need to stay focused on the details I reckon. ]
Just my view
- Forums
- ASX - By Stock
- TV2
- Ann: Quarterly Activities Report & Appendix 4C-TV2.AX
Ann: Quarterly Activities Report & Appendix 4C-TV2.AX, page-26
-
- There are more pages in this discussion • 335 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TV2 (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online